Streetbeat News

AKLI

Akili Inc

Industry

Data Processing, Hosting, and Related Services

Open

0.43

Mkt cap

34M

Volume

236K

High

0.43

P/E Ratio

-0.71

52-wk high

1.25

Low

0.43

Div yield

N/A

52-wk low

0.19

In Tuesday's intraday session, several health care stocks experienced significant movements. Akili, Cyclacel Pharmaceuticals, Eliem Therapeutics, GeneDx Hldgs, Dare Bioscience, and Lucid Diagnostics were among the gainers, with Akili leading at a 70.1% increase. On the downside, NRX Pharmaceuticals, Innovative Eyewear, Vaxxinity, Barinthus Biotherapeutics, Annovis Bio, and OpGen saw notable declines, with NRX Pharmaceuticals dropping by 23.9%.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 4:31 pm

U.S. stocks traded lower, with the Dow Jones falling over 200 points. McDonald's reported mixed Q1 results, missing EPS estimates but beating sales forecasts. Akili, AGBA Group, and Global Mofy Metaverse saw significant stock increases, while Lichen China, Vince Holding, and Medifast experienced notable declines. Oil prices rose slightly, while gold and silver fell. European and Asian markets showed mixed results, with various economic indicators reported.

Portfolio Pulse from Avi Kapoor

April 30, 2024 | 2:17 pm

Akili's stock price increased following the announcement that Shionogi has forgiven a $5.0 million long-term debt and agreed to make payments for SDT-001.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 1:17 pm

Akili announced its intention to continue seeking FDA marketing authorization for its EndeavorOTC product, a move that underscores the company's commitment to bringing its digital therapeutic solutions to market.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:54 pm

Trading for AKLI was halted but has now resumed as of 8:25:00 AM ET, following an update on quotation resumption times.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:25 pm

Akili announced a significant reduction in its workforce by approximately 46%, which includes the elimination of the company's marketing and medical affairs teams. This move is part of a broader restructuring effort to streamline operations and reduce costs.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:22 pm

Akili, Inc. (NASDAQ:AKLI) has amended its agreement with Shionogi, resulting in the cancellation and forgiveness of a $5M debt and the receipt of near-term cash payments totaling up to $18M for SDT-001, a digital ADHD treatment. Additionally, Akili is exploring strategic alternatives to maximize shareholder value, which includes a significant workforce reduction by 46% and a reduction in promotional activities. The company also plans to release its Q1 2024 financial results on May 14, 2024, without hosting an earnings call.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:21 pm

Trading for AKLI was halted at 7:55:00 a.m. ET due to pending news, indicating a significant announcement or event that could impact the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 11:55 am

In Wednesday's after-market session, several healthcare stocks showed notable movements. Acrivon Therapeutics, Amarin Corp, and Universe Pharmaceuticals were among the top gainers, with increases of 12.3%, 8.12%, and 7.47% respectively. On the losing side, Akili, BiomX, and OneMedNet experienced declines of 11.3%, 5.24%, and 4.84% respectively. Biomarin Pharmaceutical also fell by 3.49% following its Q1 earnings release.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 8:31 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. PaxMedica led the gainers with a 104.2% increase, while Motus GI Holdings experienced the largest drop among the losers, falling 26.1%. The movements reflect notable volatility in the healthcare sector, with companies ranging from biotech to pharmaceuticals experiencing shifts in their stock prices.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 12:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.